Stargardt Disease clinical trials at University of California Health

3 in progress, 1 open to eligible people

Showing trials for

  • ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

    open to eligible people ages 18 years and up

    This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

    at UCSF

  • Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

    Sorry, in progress, not accepting new patients

    The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are at least 8 years old. Enrollment is by invitation only. Funding Source - FDA OOPD

    at UCLA

  • ALK-001 on Stargardt Disease

    Sorry, accepting new patients by invitation only

    The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD

    at UCLA

Our lead scientists for Stargardt Disease research studies include .

Last updated: